The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Case Report: Pulmonary Sarcoid-Like Reaction in Patient Treated with Etanercept

Case Report: Pulmonary Sarcoid-Like Reaction in Patient Treated with Etanercept

April 15, 2022 • By Luis Lora Garcia, MD, Sneha Centala, MD, MS, Gitanjali Lobo, MD, Shahla Mallick, MD, & Diana Girnita, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Sarcoidosis is a multisystem disease characterized by noncaseating granulomas in affected tissues, mostly involving the lungs and lymph nodes.1,2 The etiology of sarcoidosis remains unknown but is thought to be due to an inflammatory response to an antigen exposure in genetically predisposed individuals.1 Tumor necrosis factor-α (TNF‑α), a pro-inflammatory cytokine, plays an essential role in this inflammatory response leading to the development of granulomas.3 Therapy with TNF-α inhibitors has proved effective for many patients with sarcoidosis.3

You Might Also Like
  • Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
  • Catastrophic Antiphospholipid Syndrome with Pulmonary Hemorrhage: A Case Report
  • Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient
Explore This Issue
April 2022

Interestingly, some TNF-α inhibitors have been recognized to induce sarcoidosislike disease.4 In 2016, a literature review found 59 cases of sarcoidosis associated with the use of TNF-α inhibitors, with 37 out of 59 associated with etanercept use.5 Fifty-two patients showed partial or complete resolution following discontinuation of the TNF-α inhibitor, either alone or along with steroid administration.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Here, we present a case of a patient with rheumatoid arthritis who developed a sarcoid-like reaction while being treated with etanercept.

Case Presentation

A 29-year-old Black woman with a past medical history of adult-onset Still’s disease (AOSD) and rheumatoid arthritis (RA) was admitted to the emergency department complaining of fever, chills and severe shortness of breath.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Five years prior to this hospitalization—the time of her initial presentation—the patient was admitted to the hospital with fever, pharyngitis, diffuse rash, myalgias, fatigue and a polyarticular arthritis. Laboratory evaluations demonstrated elevated inflammation markers (i.e., erythrocyte sedimentation rate and C-reactive protein), leukocytosis, transaminitis and rheumatoid factor. The creatine kinase was within normal limits, and no anti-nuclear antibodies or anti-citrullinated protein antibodies were detected. A chest X-ray showed no evidence of lymphadenopathy or pulmonary disease.

During the prior hospital admission, a thorough evaluation did not demonstrate evidence of an acute viral, bacterial or fungal infection. She was diagnosed with AOSD based on Yamaguchi classification criteria. She was initially treated with corticosteroids. Because the patient did not respond as anticipated, she was subsequently treated with hydroxychloroquine and methotrexate. Over the following weeks, the patient was also diagnosed with RA based on her positive RF, elevated inflammatory markers and polyarthritis present for greater than six weeks. The rash resolved quickly after diagnosis.

At that earlier time, the primary joints affected were the right third proximal interphalangeal joint and ankles.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

During the next 12 months, she was frequently lost to follow-up and took her medications inconsistently.

After one year of therapy with methotrexate and hydroxychloroquine, her rheumatologist initiated 50 mg of subcutaneous etanercept weekly. The response to this treatment was adequate, and she was gradually tapered off methotrexate and hydroxychloroquine. She continued therapy with etanercept for four consecutive years. The patient remained an everyday smoker.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: case report, drug induced, etanercept, Fellows, pulmonary sarcoidosis, SarcoidosisIssue: April 2022

You Might Also Like:
  • Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
  • Catastrophic Antiphospholipid Syndrome with Pulmonary Hemorrhage: A Case Report
  • Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient
  • Case Report: Perplexing Pulmonary Nodules

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)